Minutes

IBC Meeting

Date: April 8, 2025
Time: 2PM
Location: Zoom Meeting – Meeting ID 946 7941 3037

Call-in number: 301-715-8592
Attendees: Jermaine Lawson, Kenta Umetsu, James Novak, Stephanie Gomez, Michael Keller, Crisanto Escano, Beata Jablonska, Kerry Belton, Lumen Chao, Sydney Villanueva

Members Absent: Daniel Bobb, Kenneth Dolan, Marissa Horrigan

Guests: None

Agenda Topic	Discussion Lead	Notes	Time
Call to Order	Jermaine Lawson	The meeting was called to order when quorum was fulfilled. Attendance was documented by the administrator.	2:19PM
Vote on December's Meeting Minutes	Jermaine Lawson	The committee voted to approve 12/09/2024 meeting minutes. Vote Approve = 8	

Minutes

		Oppose = 0 Abstain = 2 Defer = 0	
Announcements	Jermaine Lawson	• New committee member Kerry Belton was introduced to the committee. • An update on the "IBC Minutes and Rosters Memorandum" from the NIH OSP was given. This requires IBCs to post meeting minutes on an external institution website and that IBC rosters will be posted on a publicly available list of IBCs registered with IBC-Registration Management System. The IBC discussed process for minutes review prior to meeting minutes being posted externally to ensure redaction of any sensitive or proprietary information. The IBC also discussed revising the IBC registration form to add an option for Principal Investigators to indicate the level of sensitivity	

Minutes

Children's National

		of the research that is submitted for review.	
Protocol Review	Jermaine Lawson	**Protocol Amendment:** 10032-IBC-Hsieh **Principal Investigator** - Michael Hsieh **Protocol Title** - Animal models of Schistosoma haematobium infection and other urogenital forms of inflammation <u>Committee Action</u> Full committee review of protocol 10032, which was amended to add bacteria strains Staphylococcus aureus, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Klebsiella pneumoniae, Acinetobacter baumannii. <u>Project Summary</u> The Hsieh lab studies urogenital infection. One aim of the study is to develop mice and hamster models to study urogenital schistosomiasis. Urogenital schistosomiasis is caused by the parasitic worm Schistosoma haematobium. The infection causes significant suffering in the form of	

Minutes

		bloody urine, anemia, leakage of protein in the urine, bacteria urinary tract co-infection, genital sores, bladder cancer and scarring of the urinary tract. S. haematobium produces a protein called IPSE, which dampens host inflammation and decreases pain in mouse models of bladder pain. The lab wants to use the developed models to determine IPSE mechanisms and to better understand the basic biology of the infection. Another aim is to study pathogenesis of uropathogenic bacteria by focusing on examining vivo pathogenesis, pathogen evolution and correlation between in vivo bacteria load, and invitro MIC data. The lab wants to understand the mechanisms of antimicrobial drug resistance and design of novel antibiotics. Amendment to add various strains of bacteria from clinical isolates. The following were added: *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Stenotrophomonas maltophilia*, *Klebsiella pneumoniae*, and *Acinetobacter baumannii*. The project summary was presented by Jermaine Lawson followed by	

		discussion of the project by the committee. <u>Remarks</u> The committee identified the following issues to be addressed by study PI. • Extensive drug resistance (XDR) gram negative bacteria are considered BSL-2+. PI needs to change the biosafety level from BSL-2 to BSL-2+ for bacteria listed in section 7 that are clinical isolates. • PI needs to provide a plan for evaluation of antibiotic resistance patterns especially if the bacteria are going to be clinical isolates that the lab intends to further test with antibiotics in vivo. • PI mentions the use of resiniferatoxin (RTX) injection into mice bladder in section 3B. PI needs to add RTX to the biological toxin section of the protocol. • There is no IRB protocol listed in section 1G. PI needs to add IRB	

		protocol information to section 1G since the clinical isolates are from patient samples. • PI needs to clearly specify why Schistosoma eggs are not infectious in project summary in section 3B. • PI did not enter any information in box 4 of the human derived material section except human urine text. PI needs to remove text and box 4 should be removed. • PI needs to unselect humans as target recipient for bacteria strains listed in section 7 since PI is not administering bacteria to human subjects. • PI intends to administer agents listed in protocol to mice. It was noted during discussion that the PI does not have an associated IACUC protocol. PI needs to engage IACUC to establish IACUC protocol for the use of agents in animals. • PI needs to indicate that animal bedding is autoclaved prior to disposal in section 10C for decontamination practices. <u>Vote</u>	

Minutes

Children's National

		The committee voted to defer approval of protocol. Approve = 0 Oppose = 0 Abstain = 0 Defer = 10 The protocol will go back to the committee for review after identified issues are addressed by the PI.	
Protocol Review	Jermaine Lawson	**Protocol Amendment:** 10026-IBC-Jaiswal **Project PI** – Jyoti Jaiswal **Protocol Title** – Using cytomegalovirus to understand the regulation of calcium dynamics at mitochondria associated membranes <u>Committee Action</u> Full committee review of Protocol 10026, which was amended to add cytomegalovirus. <u>Project Summary</u> The Jaiswal lab aims to understand how HCMV infection affects the transfer of calcium between the Endoplasmic reticulum and the mitochondria. This will be done by altering the properties of the membrane contacts between the endoplasmic reticulum and the mitochondria - known as mitochondria	

		associated membranes (MAM). MAM dysfunction has been associated with cancer, Alzheimer's disease, neurodegenerative disease, and pulmonary hypertension. The lab wants to identify how the MAM proteome change by the presence of the hCMV protein - vMIA (mitochondria-localized inhibitor or apoptosis) and identify how vMIA regulates MAM Ca2+ dynamics and affect mitochondrial function. This is an amendment to add hCMV, which the lab intends to use in their invitro studies. The project summary was presented by Jermaine Lawson followed by protocol discussion by the committee. <u>Remarks</u> The committee identified the following minor issues to be addressed by project PI after review and discussion of the submitted project. • PI needs to add missing units for titers listed in viral vector section of section 6a. • PI needs to clarify if centrifugation is used in any process involving the use of hCMV.	

Minutes

		• PI needs to add language in the project summary to indicate that pregnant women are at higher risk for work with hCMV. • Hazard warning signage should be posted to indicate the use of a teratogen (hCMV) in areas of use <u>Vote</u> The committee voted to approve the protocol. Approve = 10 Oppose = 0 Abstain = 0 Defer = 0	
Adjournment	Jermaine Lawson	The meeting was adjourned at 3:00PM.	3:00PM